News in Lung Immunotherapy - prIME Oncology
Webcast
Webcast

News in Lung Immunotherapy

Updates From Recent Meetings – Webcast From Immuno-Oncology Virtual Grand Rounds

Not a member of My prIME? Join now for instant access.

Did you miss the live broadcast? Stay engaged in recent updates and key findings in NSCLC immuno-oncology with this webcast from our virtual grand rounds series.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credits

Release Date

Release Date

Dec 6, 2018

Expiration Date

Dec 6, 2019

News in Lung Immunotherapy: Updates from Recent Meetings
Enriqueta Felip, MD, PhD

  • Enriqueta Felip, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, melanoma, or bladder cancer.

After successful completion of this educational activity, participants should be able to:

  • Examine the evidence for the role of biomarkers in immuno-oncology and how to apply them in clinical practice
  • Select optimal immunotherapy approach for patients with cancer
  • Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
  • Develop strategies to recognize and manage adverse events resulting from the use of immunotherapies

Best Practices in Melanoma Immunotherapy

Dirk Schadendorf, MD

A Practical Application of Data in Bladder Cancer Immunotherapy

Ronald de Wit, MD, PhD

Immunotherapy in Lung Cancer: The News From Major Lung Conferences in 2018

Benjamin Besse, MD, PhD

Decision-Making in NSCLC Immunotherapy

Solange Peters, MD, PhD

Challenging Cases in Melanoma Immunotherapy

Caroline Robert, MD

This educational activity is supported by a grant from Merck Sharp and Dohme Corp.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

 

Disclosure of Relevant Financial Relationships

prIME Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to prIME Oncology policy. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Felip has disclosed board membership, consulting fees, and honoraria for promotional speaker’s bureaus from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Merck, Merck Sharpe and Dohme, Novartis, Pfizer, Roche, and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.